U.S. gov awards CSL Biotherapies contract for influenza pandemic preparedness

Friday, September 14, 2012 12:07 PM

CSL Biotherapies, a King of Prussia, Penn.-based subsidiary of CSL Limited, a manufacturers of influenza vaccines, has been awarded a contract by the U.S. Department of Health and Human Services to supply pre-pandemic and pandemic vaccine antigens and related services to the U.S. national stockpile.

The U.S. government may request CSL Biotherapies to manufacture and store bulk antigen that can be used against influenza strains with pandemic potential. The company may also be called upon to develop working virus 'seeds' for other manufacturers and to formulate, fill and finish bulk stored antigen.

Funding for the CSL Biotherapies contract is provided solely by the U.S. Department of Health and Human Services’ office of the assistant secretary for preparedness and response, biomedical advanced R&D authority. The contract has a maximum potential value of $1.5 billion if all optional activities are exercised over the duration of the contract.

"We are very pleased to again be working with the U.S. government on its pandemic preparedness efforts," said Dr. John Anderson, senior vice president of CSL Biotherapies. "CSL Biotherapies is committed to helping to protect the American public against the potential impact of an influenza pandemic. We are proud to contribute our 45 years of successful influenza vaccine manufacturing experience to the U.S. National Strategy for Pandemic Influenza."

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

July 28

WCG acquires Alliance Biosciences to expand its biosafety oversight capabilities, ensure compliance

Facilitated review meetings for protocol design catching on, decreasing amendments, complexity

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

July

IRB market consolidating rapidly
Private equity driving a new commercial ethical review landscape

Lessons learned from medical device trials
Smaller, faster, more flexible trials hold important insights for pharmaceutical innovation

Already a subscriber?
Log in to your digital subscription.

Purchase the July issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

June

CRO market poised for growth and consolidation
Sponsors expanding pipelines, shrinking infrastructure fuel strategic outsourcing

Strategies for success evolving in phase I space
Sites see increasing complexity, more patients, greater focus on efficacy

Already a subscriber?
Log in to your digital subscription.

Purchase the June issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs